Hoth Therapeutics (NASDAQ:HOTH) shares rose by a staggering 215% today following significant breakthrough in cancer treatment. Their Phase 2a clinical trial of Hoth's topical gel HT-001 has shown 100% ...

Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don't make them change their opinion towards a ...

In the open-label PK cohort, 100% of evaluable patients achieved clinical response by Week 6, accompanied by an approximate 50% reduction in investigator-assessed disease severity (using the ARIGA ...

Detailed price information for Hoth Therapeutics Inc (HOTH-Q) from The Globe and Mail including charting and trades.

Regulatory Clearance in Spain Advances Randomized, Placebo-Controlled Study; Patients Show Meaningful Reductions in ...

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Hoth Therapeutics HOTH is a clinical-stage ...

NEW YORK, June 18, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH), a clinical-stage biopharmaceutical company focused on breakthrough therapies, today announced that it has regained full ...

Early observations suggest that the vehicle-treated Alzheimer's mice exhibit a larger population of reactive astrocytes, while the HT-ALZ treated groups show fewer reactive astrocytes, pointing to a ...

Patients will be able to enroll in trial at any time and regardless of failure from other therapeutics This is a randomized, double-blind, placebo-controlled, multi-center Phase 2a dose-ranging study ...

Hoth Therapeutics Inc. (NASDAQ:HOTH) on Tuesday announced combined findings from multiple preclinical programs evaluating its precision antisense candidate HT-KIT. HT-KIT is a precision antisense ...